Novartis ’ Kymriah receives FDA approval for B-cell precursor ALL treatment

The US Food and Drug Administration (FDA) has approved Novartis ’ Kymriah (tisagenlecleucel) suspension for intravenous infusion to treat patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory or in…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news